Treatment of non-alcoholic fatty liver disease
- 1 December 2007
- journal article
- Vol. 3 (6) , 1153-1163
Abstract
Non-alcoholic fatty liver disease, defined as the presence of macrovascular steatosis in the presence of less than 20 gm of alcohol ingestion per day, is the most common liver disease in the USA. It is most commonly associated with insulin resistance/type 2 diabetes mellitus and obesity. It is manifested by steatosis, steatohepatitis, cirrhosis, and, rarely, hepatocellular carcinoma.Keywords
This publication has 102 references indexed in Scilit:
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic SyndromeJAMA, 2004
- Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitisHepatology, 2003
- Long–Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis CHepatology, 2003
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Imaging of Hepatic SteatosisSeminars in Liver Disease, 2001
- Ethanol and Arachidonic Acid Increase α2(I) Collagen Expression in Rat Hepatic Stellate Cells Overexpressing Cytochrome P450 2E1Journal of Biological Chemistry, 2000
- Body-Mass Index and Mortality in a Prospective Cohort of U.S. AdultsNew England Journal of Medicine, 1999
- Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosisJournal of Hepatology, 1996
- Hepatic effects of dietary weight loss in morbidly obese subjectsJournal of Hepatology, 1991